RVP

Business Context and Reporting Period

Company: Retractable Technologies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2008
Business Overview: The Company designs, develops, manufactures, and markets safety syringes and other safety medical products. Primary products include the VanishPoint® syringe line. Manufacturing occurs in Little Elm, Texas, and via a contract manufacturer in China (Double Dove), which supplied approximately 76.7% of finished products in Q1 2008.

Key Financial Metrics

Note: Working Capital calculated as Total Current Assets ($48,518,342) minus Total Current Liabilities ($8,229,619).

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 8.0% to $5.3 million. This was driven by a 58.0% drop in international sales due to the absence of PATH (Program for Appropriate Technology in Health) shipments, partially offset by a 13.3% increase in domestic sales.
• Unit Volume: Overall unit sales decreased 20.7%. Domestic unit sales increased 7.5%, while international unit sales fell 54.9%.
• Cost Structure: Cost of manufactured product decreased, but the average cost per unit sold increased by 11.2% due to lower volumes. Gross profit improved slightly despite lower revenue.
• Operating Expenses: Total operating expenses increased 9.1% to $4.36 million. General and administrative costs rose due to legal expenses and compensation. Research and development costs increased due to validation and consulting costs. Sales and marketing expenses decreased due to fewer trade shows and lower travel costs.
• Liquidity: Cash and cash equivalents decreased by approximately $1.3 million during the quarter. Net cash used by operating activities was $1.07 million.

Guidance, Outlook, Risks, and Contingencies

Outlook and Capital Requirements

• Liquidity: Management does not intend to raise equity capital in 2008. The Company relies on cash reserves (approx. $39.2 million), operations, and debt financing.
• Expansion: The Company plans to expand its warehouse and add a Clean Room in Q2 2008, funded by a pending $4.2 million loan from Lewisville State Bank.
• Licensing: A licensing agreement with BTMD (China) expired May 13, 2008. The Company is negotiating an extension and expects future royalty payments once Chinese government requirements are met.
• Cost Cutting: If market access remains limited and cash becomes insufficient, the Company may reduce production, workforce, and salaries, and defer royalty payments.

Risks and Legal Proceedings

• Market Access: The Company alleges monopolistic practices by Becton Dickinson (BD) block access to hospital markets. Litigation against BD is ongoing regarding antitrust violations and patent infringement.
• Patent Litigation:
  • vs. Abbott: Lawsuit for breach of contract and fraud; appeal pending in the Fifth Circuit.
  • vs. BD: Multiple suits filed regarding patent infringement and antitrust violations. BD has counterclaimed for patent invalidity.
  • vs. OMI: Sued in Australia and the U.S. regarding patent infringement and false advertising.
  • MedSafe Technologies: Sued the Company and BD alleging infringement of U.S. patent no. 6,074,370.
• Supplier Concentration: Roughly 76.7% of finished products are obtained from Double Dove in China. Disruption could impact supply of 5cc and 10cc syringes.
• Preferred Stock Dividends: Significant dividends are in arrears across multiple series of Class B Preferred Stock, totaling over $13 million in cumulative arrearages as of March 31, 2008.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $39.2 million cash reserve against the $1.1 million quarterly operating cash burn and upcoming $4.2 million debt obligation.
• Legal Outcomes: Monitor the status of the Fifth Circuit appeal regarding Abbott and the patent trials against BD and OMI, as these directly impact market access and potential damages.
• BTMD Licensing: Confirm the status of the renegotiation with BTMD, as expected royalty revenue is currently delayed.
• Supply Chain: Assess the risk of reliance on a single Chinese manufacturer (Double Dove) for the majority of production.
• Preferred Stock Arrears: Review the impact of over $13 million in unpaid preferred dividends on the ability to pay common dividends or redeem junior stock.